Quote · The Prof G Pod with Scott Galloway
Why People Are Losing Faith in Healthcare
Where this was said
The Peptide Craze and the Healthcare Trust Crisis
At 29:20 · chapter starts 25:25
Scott Galloway asks for a plain-English explainer on peptides — a word now everywhere in wellness culture. Ricks obliges with a short biochemistry lesson: a peptide is simply a chain of amino acids, a foundational term in biology, and the fact that online marketing has made it sound exotic says more about modern commerce than science. His critique of the unregulated peptide market is pointed: these are 'unstudied medicines,' substances sold without clinical trials, safety data, or any third-party verification of what's actually in them. Some mimic growth hormone — which is also pro-tumor growth, Ricks notes drily. But the more revealing part of his answer is the sociological diagnosis: the peptide boom is a symptom of a genuinely broken consumer healthcare experience. No prices, long waits, condescension, information asymmetry — all of it has driven people to take agency online, armed with N-of-1 anecdotes and biochemistry they can't verify. 'That's not science,' Ricks says, but he acknowledges the underlying frustration is legitimate. The healthcare system has earned some of the distrust now being directed at it.
The booming online peptide market is selling substances without clinical trials, safety data, or FDA approval. Lilly's CEO calls them 'unstudied medicines' — and connects the craze to justified rage at a broken healthcare system that leaves patients feeling financially and informationally powerless.
Lilly bet on GLP-1s in 2018 when nobody else was — obesity was considered a non-market. Combined with a 5-year cut in R&D cycle time and a singular Midwestern execution culture, those three factors compounded into a trillion-dollar market cap and fivefold stock return.
